THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Munir, Shirin
Afroz, Sharmin
Collins, Peter L.
Buchholz, Ursula J.
Mueller, Steffen
Abrégé
Disclosed are live-attenuated human parainfluenza virus (HPIV) immunogenic molecules comprising at least one codon-pair deoptimization (CPD) in an open reading frame (ORF) of a HPIV gene that encodes at least one HPIV protein. In addition, pharmaceutical compositions comprising the immunogenic molecules, methods and kits for using the immunogenic molecules and pharmaceutical compositions, and methods of making the immunogenic molecules are disclosed, in accordance with aspects of the invention.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Wohlstadter, Jacob N.
Sigal, George
Debad, Jeffery
Biebuyck, Hans
Krai, Priscilla
Kishbaugh, Alan
Dzantiev, Leonid
Shelburne, Christopher
Harkins, Seth B.
Fulkerson, John
Jakubik, Jocelyn Jean
Douek, Daniel
Narpala, Sandeep
Chowdhury, Ananda
Spaulding, Alicen
Serebryannyy, Leonid
Mcdermott, Adrian
O'Connell, Sarah
Abrégé
The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
3.
IMPROVED GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Venditti, Charles P.
Chandler, Randy J.
Abrégé
Polynucleotide expression cassettes comprising synthetic polynucleotides encoding human propionyl-CoA carboxylase alpha (synPCCA) are described herein. Related recombinant expression vectors, recombinant adeno-associated viruses (rAAVs), and compositions are also described. Also described are methods of treating a disease or condition mediated by propionyl-CoA carboxylase, comprising administering to a subject in need thereof a therapeutic amount of any of the polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
4.
POLYFLUORINATED THALIDOMIDE ANALOGS AND USES THEREOF
THE UNITED STATES OF AMERICA, as represented by the secretary, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
UNIVERSITY OF BONN (Allemagne)
Inventeur(s)
Figg, William D.
Chau, Cindy H.
Gütschow, Michael
Steinebach, Christian
Barton, Blaire E.
Collins, Matthew K.
Abrégé
Polyfluorinated thalidomide analogs have a structure according to formula I, wherein R is aliphatic. The compounds may be used to inhibit cancer cell proliferation and/or to treat subjects with cancer or an inflammatory process. In some aspects, the cancer is multiple myeloma. In certain aspects, the compounds are used to inhibit proliferation of drug-resistant multiple myeloma cells and/or to treat subjects with drug-resistant multiple myeloma.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Vishwasrao, Harshad D.
Abrégé
In some instances, a system for rapid spectral unmixing using spectrally interpolated background reduction (SIBR) is provided. The system comprises a device comprising an excitation light source and a detector. The system further comprises a control system configured to: obtain a plurality of excitation spectra for a plurality of fluorophores that are used to stain a sample; determine a plurality of chosen wavelengths and a plurality of chosen light intensities for the plurality of fluorophores; obtain a first detection of the sample based on using a set of first wavelengths from the plurality of chosen wavelengths and a set of first light intensities; obtain a second detection of the sample based on using a set of second wavelengths from the plurality of chosen wavelengths and a set of second light intensities; and output a SIBR quantity.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Qin, Haiying
Mackall, Crystal L.
Fry, Terry J.
Abrégé
An embodiment of the invention provides chimeric antigen receptor (CAR) amino acid constructs. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. Methods of making the CAR constructs are disclosed.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/395 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de champignons provenant de levures provenant de Saccharomyces
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Tan, Joshua Hoong Yu
Dacon, Cherrelle
Abrégé
Disclosed are bispecific antibodies, including dual variable domain immunoglobulins that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Ende, Zachary Shai
Sambhara, Suryaprakash
Abrégé
The present disclosure relates to a rapid method for producing antibodies. The method uses OE-PCR to join templates encoding antibody domains, thereby forming a linear expression cassette encoding a fusion protein comprising the antibody domains. A self-cleaving peptide is positioned between variable domains such that translation of the linear expression cassette produces individual proteins, each comprising a light or heavy chain variable region. These individual proteins can then join to form an antibody. The disclosure also provides Methods of producing linear expression cassettes as well as methods of using such cassettes for treating individuals.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
St. Croix, Bradley
Bajgain, Pradip
Feng, Yang
Abrégé
CD276 (also known as B7H3) is highly expressed in the stroma of most solid tumors and is also frequently overexpressed by tumor cells, making CD276 an important target for anti-cancer therapy. Fully human monoclonal antibodies that bind CD276 are described. Chimeric antigen receptors (CARs) generated using the CD276 antibodies are also described. The monoclonal antibodies, CARs and other antibody conjugates can be used for the detection and treatment of CD276-positive cancers.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
10.
2B SEROTONIN RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Jacobson, Kenneth A.
Tosh, Dilip K.
Abrégé
Disclosed are compounds of formulas (I) and (II), a salt thereof, or an optical isomer thereof, wherein R1-R32B2B serotonin receptor selective antagonists, pharmaceutical compositions comprising such compounds, and methods of treating various diseases and conditions in an animal including fibrosis of the lung, skin, coronary, and liver, pulmonary arterial hypertension, valvular heart disease, pain, and cancer by the use of these compounds.
C07D 473/40 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'halogènes ou des radicaux perhalogénoalkyles liés directement en position 2 ou 6
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
O'Keefe, Barry R.
Du, Lin
Wilson, Brice A.P.
Zhang, Ping
Wang, Dongdong
Martinez Fiesco, Juliana A.
Li, Ning
Moore, William J.
Abrégé
Disclosed is a class of kinase inhibitors of formula (I) or formula (II). Related pharmaceutical compositions and methods of using the kinase inhibitors are also disclosed.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
12.
IDENTIFICATION OF SEQUENCE VARIANTS OF THE ERVMER34-1 SEQUENCE FAMILY AND USE IN ANTI-CANCER THERAPIES
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Schlom, Jeffrey
Hamilton, Duane H.
Donahue, Renee N.
Palena, Claudia M.
Abrégé
The invention provides a protein or polypeptide derived from ERVMER34-1. The invention further provides a nucleic acid encoding the inventive protein or polypeptide, a vector comprising the nucleic acid, cells comprising the protein or polypeptide, nucleic acid, and/or vector, and composition, such as a pharmaceutical composition, comprising any of the foregoing. These reagents (the inventive protein or polypeptide, nucleic acid, vector, cell, or composition thereof) are useful for immunological treatment and prophylaxis of diseases, particularly cancers.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Fitzgerald, David J.
Antignani, Antonella
Sarnovsky, Robert
Abrégé
e.ge.g., humanized monoclonal antibodies and antigen binding fragments) that specifically bind epidermal growth factor receptor variant III (EGFRvIII) and/or gene-amplified EGFR, as well as conjugates and chimeric antigen receptors (CARs) including such antibodies. Also provided are nucleic acid molecules encoding an antibody, conjugate, or CAR disclosed herein, and host cells expressing the nucleic acid molecules. Further disclosed are methods of using the disclosed compositions, for example, for treating or detecting a tumor, such as a tumor expressing EGFRvIII and/or gene-amplified EGFR.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
14.
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Maminishkis, Arvydas
Abrégé
A shipping container for the support and shipment of a system for supporting at least one live cell includes a container and a lid configured to be removably coupled together to form a container cavity therebetween. A lower stabilization support and an upper guard are provided for supporting the system. The lower stabilization support is sized to be received within the container, and includes an upwardly opening recess configured to receive and support at least a portion of the system. The upper guard includes a lower surface that is sized to be at least partially received within an upwardly directed system cavity of the system. In this way, the lower stabilization support and upper guard are configured to securely support the system within the container cavity between the container and the lid.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Levin, Noam
Rosenberg, Steven A.
Kim, Sanghyun
Lowery, Iii, Frank J.
Parkhurst, Maria R.
Bera, Alakesh
Abrégé
Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with aspartic acid, valine, or arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Tolia, Niraj
Dickey, Thayne
Patel, Palak
Abrégé
Plasmodium yoeliiPlasmodium falciparumPlasmodium falciparum than AMA1 or AMA1-RON2L complex vaccination. This indicates that SBD1 directs neutralizing antibody responses to strain-transcending epitopes in AMA1 that are independent of RON2L binding. This work underscores the importance of neutralization mechanisms that are distinct from RON2 blockade. The stable single-component SBD1 immunogen elicits potent strain-transcending protection that may drive the development of next-generation vaccines for improved malaria and apicomplexan parasite control.
THE UNITED STATES OF AMERICA, as represented by the secretary, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Bash, Margaret C.
Matthias, Kathryn
Abrégé
Disclosed are isolated PorA-PorB-RmpM-LpxL1-Nmeningitidis meningitidis and compositions including an effective amount of OMVs produced from these PorA-PorB-RmpM-LpxL1-N. meningitidisNeisseriaN. meningitidisN. gonorrhoeae. N. gonorrhoeae.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Shamim, Khalida
Chen, Catherine
Hu, Xin
Huang, Wenwei
Huang, Xiuli
Carvalho Padilha, Elias
Sanderson, Philip
Shah, Pranav
Xu, Xin
Zheng, Wei
Newman, Amy Hauck
Abrégé
33 receptor modulators, inclusive of antagonists and agonists, with alleviated hERG liability and desirable pharmacokinetic properties, as well as compositions comprising, kits comprising, methods of administering, and methods of synthesizing the same.
C07D 295/13 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles avec les atomes d'azote du cycle et les atomes d'azote substituants liés à la même chaîne carbonée, qui n'est pas interrompue par des cycles carbocycliques à une chaîne acyclique saturée
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance
A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/451 - Pipéridines non condensées, p. ex. pipérocaïne ayant un carbocycle lié directement à l'hétérocycle, p. ex. glutéthimide, mépéridine, lopéramide, phencyclidine, piminodine
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
20.
EPIDITHIODIKETOPIPERAZINE ANALOGS AND METHODS OF USE
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE TRUSTEES OF INDIANA UNIVERSITY (USA)
Inventeur(s)
Figg, William D.
Snaddon, Thomas N.
Chau, Cindy H.
Napoli, Giulia C.
Barton, Blaire E.
Pearson, Colin M.
Abrégé
Epidithiodiketopiperazine (ETP) analogs and methods of using the analogs are disclosed. The ETP analogs may have a structure according to Formula I (I), or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof, where R1is aryl or heteroaryl; R2is ‑H, aliphatic, heteroaliphatic, aryl, or heteroaryl; and R3and R4independently are aliphatic, heteroaliphatic, ‑H, –C(O)ORa, or ‑C(O)Ra. Each Ra independently is ‑H, aliphatic, or heteroaliphatic. The compounds may be used to inhibit hypoxia‑inducible factor 1 (HIF-1) activity and/or to ameliorate conditions characterized at least in part by abnormal levels of HIF‑1 activity. (I)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Dandey, Venkata P.
Borgnia, Mario J.
Peele, Wyatt A.
Huang, Tony Jun
Yang, Kaichun
Abrégé
An apparatus for preparing samples for cryogenic electron microscopy includes an acoustic transducer having a sample receiving area for receiving one or more liquid droplets. An acoustic signal generator is coupled to the acoustic transducer. Control circuitry is coupled to the acoustic signal generator, the control circuitry configured to cause the acoustic signal generator to generate a first acoustic signal at a first frequency for a first time period and subsequently to generate a second acoustic signal at a second frequency for a second time period.
22.
DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Newman, Amy Hauck
Kumar, Vivek
Shaik, Anver Basha
Abrégé
Disclosed herein are novel methods of treating substance use disorders, mitigating the development of substance addiction, reducing the severity of substance withdrawal symptoms, or reducing or preventing substance relapse by providing to the patient a therapeutically effective amount of a Medication Assisted Treatment agent and a selective dopamine D3 receptor antagonist/partial agonist. In addition, the D3 antagonists/partial agonists described herein may be used to augment the effectiveness of current Medication Assisted Treatment regimens (e.g. methadone or buprenorphine) for the treatment of substance use disorders, including opioid use disorders.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Venditti, Charles P.
Pavan, William J.
Chandler, Randy J.
Abrégé
The present disclosure provides compositions for viral gene therapy, e.g. Adeno-Associated virus-directed gene therapy, and methods of using the same for the treatment and/or prevention of cholesterol storage diseases or disorders, such as Niemann-Pick disease, Type C.
THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Fratta, Pietro
Brown, Anna Leigh
Wilkins, Oscar
Keuss, Matthew
Ward, Michael
Hill, Sarah
Abrégé
Antisense oligonucleotides (ASOs) are provided which are capable of modulating splicing by preventing inclusion of an UNC13A cryptic exon into an UNC13A mature mRNA. Such ASOs may be used as a medicament, for example, to treat neurodegenerative disorders, particularly those associated with TDP-43 pathology.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Chiorini, John A.
Abrégé
In a first aspect, the invention provides a genetic vector, such as a non-encapsulated vector, comprising a first DNA sequence encoding a polypeptide able to form viral capsids with a CAP (capsid) protein of a copiparvovirus and a second DNA sequence comprising a non-copiparvovirus promoter operably linked to the first DNA sequence. In a second aspect, the invention provides an encapsulated genetic vector comprising a capsid comprising polypeptide able to form viral capsids with a CAP (capsid) protein of a copiparvovirus and a genome comprising either non-copiparvovirus DNA and can include adenoviral ITRs or copiparvovirus asymmetric terminal elements. Compositions comprising the inventive vectors, as well as methods of making such and using such, are provided as well.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Kwong, Peter
Oila, Adam
Rawi, Reda
Zhou, Tongqing
Cheng, Cheng
Abrégé
Immunogens comprising a recombinant HIV-1 Env ectodomain trimer stabilized in a prefusion closed conformation and wherein protomers of the trimer are genetically fused via peptide linkers are provided. In the recombinant HIV-1 Env ectodomain trimer, the C terminus of a first protomer in the trimer is fused to the N terminus of a second protomer in the trimer by first peptide linker, and the C terminus of the second protomer is fused to the N terminus of a third protomer in the trimer by a second peptide linker. In several aspects, the first and second peptide linkers contain N-linked glycan sequons, the glycosylation of which reduces the immunodominance of the membrane-proximal base of the trimer. In several implementations, the immunogen can be used to elicit an immune response to HIV-1 in a subject.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (USA)
BIOLOGICKE CENTRUM AV CR, V. V. I. (République tchèque)
Inventeur(s)
Grigg, Michael E.
Pszenny, Viviana
Sardinha Da Silva, Aline
Dubey, Jitender P.
Lukes, Julius
Abrégé
Apicomplexa or EuglenozoaToxoplasma gondiiToxoplasma gondiiToxoplasma gondii IFT88, SRS15A, SRS15B, and/or SRS15C, SRS26B protein or homolog or ortholog thereof, or a combination of two or more thereof. Methods of vaccinating animals using such vaccine compositions also are provided.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
29.
HUMAN MONOCLONAL ANTIBODIES THAT TARGET THE RH5 COMPLEX OF BLOOD-STAGE PLASMODIUM FALCIPARUM
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Ho, Mitchell
Hong, Jessica Diana
Buffington, Jesse Dean
Duan, Zhijian
Adhya, Sankar
Li, Xintian
Abrégé
HHH) phage display library panned against a stabilized S2 subunit trimer from the SARS-CoV-2 spike protein. The S2 subunit-specific antibodies, and conjugates thereof (including l phage particles expressing S2-specific single-domain antibodies), can be used for the diagnosis and treatment of a coronavirus infection.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Buchholz, Ursula
Munir, Shirin
Luongo, Cindy
Collins, Peter Leon
Le Nouen, Cyril
Kaiser, Jaclyn Abbey
Abrégé
Recombinant murine pneumonia viruses (rMPV) expressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein and their use as live-attenuated virus vaccines against SARS-CoV-2 is described. The rMPV expressing S protein are safe, immunogenic, and efficacious for protecting a subject again SARS-CoV-2 infection and disease, as demonstrated in a non-human primate model. The rMPV induce a strong systemic and mucosal antibody response against the SARS-CoV-2 S protein. Furthermore, a single dose of the live-attenuated rMPV induced strong protection against SARS-CoV-2 challenge, while two doses were fully protective.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Hinrichs, Christian S.
Rosenberg, Steven A.
Abrégé
Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Roberts, Mary Scott
Collins, Michael T.
Hartley, Iris R.
Gafni, Rachel I.
Roszko, Kelly B.L.
Abrégé
The present disclosure provides a method of treating hypoparathyroidism, such as hypoparathyroidism associated with a prior surgical procedure (e.g., a post-surgical hypoparathyroidism (PSH)), in a subject in need thereof, with a therapeutically effective amount of a compound of formula (I), in particular CLTX-305. In particular, a therapeutically effective amount of the compound of formula (I) (e.g., CLTX-305) reduces symptoms associated with hypoparathyroidism and minimizes hypercalciuria in hypoparathyroidism (e.g., PSH) subjects.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Deng, Zhi-De
Pritchard, Bruce Allen
Kim, Junghee
Dold, George Raphael
Schor, Robert Hyllel
Lisanby, Sarah Hollingsworth
Abrégé
Methods and systems are provided herein for a multichannel individualized stimulation therapy (MIST) system. In one example, a MIST system includes a device comprising a plurality of stimulation electrodes and a plurality of isolated current sources (ICS), wherein the device is reconfigurable to vary positions and dosimetry of pulses of stimuli applied to a patient.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/372 - Aménagements en relation avec l'implantation des stimulateurs
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Chiorini, John A.
Hoffman, Matthew P.
Abrégé
Administration of aquaporin-1 (AQP1) complementary deoxyribonucleic acid (cDNA) to a salivary gland prior to treatment with ionizing radiation (IR) prevents the subsequent IR-induced loss in function. The administration of AQPI (e.g., human AQP1: hAQP1) prior to IR treatment (e.g., in patients with head and neck cancer) can reduce or prevent IR-induced salivary hypofunction, resulting in an elevated salivary output.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Duyn, Jozef Henricus
Van Gelderen, Peter
De Zwart, Jacobus Adrianus
Abrégé
Various methods and systems are provided for patterned multi-slice excitation (PME) magnetic resonance image (MRI). In one example, a method for imaging a patient according to a PME MRI slice acquisition protocol includes, during a first pulse interval, applying a first radiofrequency (RF) pulse together with a first slice selection gradient to excite a first slice and a second slice, the second slice following the first slice in the slice acquisition protocol, and acquiring MR signals of only the first slice; and during a second pulse interval following the first pulse interval, applying a second RF pulse together with a second slice selection gradient to excite the second slice and a third slice, the third slice following the second slice in the slice acquisition protocol, and acquiring MR signals of only the second slice.
G01R 33/483 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p. ex. spectroscopie in vivo
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
38.
ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F]FLUOROCELLOBIOSE AND DEOXY-[18F]FLUOROCELLOTRIOSE
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Bhattacharyya, Falguni
Swenson, Rolf E.
Hammoud, Dima A.
Shah, Swati
Shi, Zhen-Dan
Abrégé
Enzymatic radiosyntheses of deoxy-[18F]fluorocellobiose and deoxy-[18F]fluorocellotriose are disclosed. Deoxy-[18F]fluorocellobiose is synthesized in 1-2 hours from (i) deoxy-[18F]fluoroglucose, glucose-1-phosphate, and a cellobiose phosphorylase (CBP), or (ii) deoxy-[18F]fluoroglucose-1-phosphate, glucose, and a CBP. Deoxy-[18F]fluorocellotriose is synthesized in 1-2 hours from (i) deoxy-[18F]fluoroglucose, glucose-1-phosphate, CBP, and a CBP variant, (ii) deoxy-[18F]fluorocellobiose, glucose-1-phosphate, and a CBP variant, or (iii) deoxy-[18F]fluoroglucose-1-phosphate, cellobiose, and a CBP variant.
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
C12P 19/00 - Préparation de composés contenant des radicaux saccharide
C07H 3/06 - Oligosaccharides, c.-à-d. saccharides comportant de trois à cinq radicaux saccharide liés entre eux par des liaisons glucosidiques
39.
1-THIOXO-2,4-DIHYDROTHIENO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN-5(1 H)-ONE DERIVATIVES AS ALLOSTERIC INHIBITORS OF THE POLO-LIKE KINASE 1 (PLK1) POLO BOX DOMAIN (PBD) FOR THE TREATMENT OF CANCER
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Lee, Kyung S.
Jacobson, Kenneth A.
Park, Jung-Eun
Lee, Hobin
Pongorne Kirsch, Klara
Abrégé
Disclosed are allosteric inhibitors of the Plk1 Polo Box Doamin (PBD), which are useful in treating cancers by inducing mitotic block of the cancer cells. Examples of such inhibitors include compounds of formula (I) and (II), as well as pharmaceutically acceptable salt thereof, wherein X, R1, R2, and R3 are as defined. Also disclosed are pharmaceutical compositions containing a compound or salt thereof and a method of treating cancer in an animal by administering to the animal an effective amount of the compound or the pharmaceutical composition.
C07D 263/58 - BenzoxazolesBenzoxazoles hydrogénés avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement en position 2
C07D 333/78 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant un atome de soufre comme unique hétéro-atome du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques condensés avec des cycles autres que des cycles à six chaînons ou avec des systèmes cycliques contenant de tels cycles
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Kim, Sanghyun
Zacharakis, Nikolaos
Levin, Noam
Rosenberg, Steven A.
Abrégé
Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53Y220Cor human p53R175H. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Williams, William V.
Lopez-Lago, Miguel
Berzofsky, Jay
Olkhanud, Purevdorj
Seishima, Noriko
Abrégé
The present disclosure provides engineered mammalian dendritic cells that express exogenous Major Histocompatibility Complex (MHC) class II alleles. Methods for using the engineered mammalian dendritic cells of the present disclosure for semi-allogeneic and autologous dendritic cell-based immunotherapy in a subject are also provided.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Michaelides, Michael
Gomez, Juan, L.
Rice, Kenner, C.
Sulima, Agnieszka
Baumann, Michael, H.
Abrégé
The invention provides a fluorinated compound of Formula (I): a deuterated or tritiated variant thereof, or a pharmaceutically acceptable salt thereof, wherein at least one C–H bond on the compound of Formula (I) is replaced with a C–F bond or a C–18F bond. The invention further provides compositions comprising the fluorinated compound, a deuterated or tritiated variant thereof, or a pharmaceutically acceptable salt thereof, and methods of using the fluorinated compound, a deuterated or tritiated variant thereof, or a pharmaceutically acceptable salt thereof.
C07D 235/06 - BenzimidazolesBenzimidazoles hydrogénés avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement en position 2
C07D 235/10 - Radicaux substitués par des atomes d'halogènes ou des radicaux nitro
C07D 235/12 - Radicaux substitués par des atomes d'oxygène
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Bharti, Kapil
Zhang, Congxiao
Fausey, Andrew Jacob
Sharma, Ruchi
Abrégé
Methods are disclosed for treating or reducing the risk of developing age-related macular degeneration (AMD) in a subject. These methods can include selecting a subject having, or at risk of developing, the AMD and administering to the subject an effective amount of an agent that inhibits HERV-K. An agent that inhibits HERV-K includes, but is not limited to, an antibody, an inhibitory RNA molecule, an anti-retroviral agent, a CRISPR/Cas13 system targeting HERV-K, as well as angiogenin. A CRISPR/Cas13 system targeting HERV-K is also provided. These methods also can include selecting a subject having, or at risk of developing, the AMD and administering to the subject an effective amount of an agent that increases ANG activity.
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
University of Kansas (USA)
Northwestern University (USA)
Inventeur(s)
Rudloff, Udo
Kozlov, Serguei
Marugan, Juan Jose
Huang, Sui
Patnaik, Samarjit
Braisted, John C.
Southall, Noel T.
Ferrer, Marc
Dextras, Christopher
Haslam, John
Baltezor, Michael
Abrégé
Disclosed are pharmaceutical formulations comprising a compound of formula (I):
Disclosed are pharmaceutical formulations comprising a compound of formula (I):
Disclosed are pharmaceutical formulations comprising a compound of formula (I):
in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
45.
Exo VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Pommier, Yves Georges
Huang, Shar-Yin Naomi
Abrégé
The disclosure provides a method of treating or preventing a bacterial infection in a subject comprising administering a therapeutically effective amount of a combination of a bacterial type IIA topoisomerase inhibitor, or a pharmaceutically acceptable salt thereof and a compound Formula I, or a pharmaceutically acceptable salt thereof, to the subject, where the compound of Formula I is (Formula (I)) where the variables, e.g. Y1, Y2, and R1-R4, are described herein. The bacterial type IIA topoisomerase inhibitor can be a quinolone antibiotic such as ciprofloxacin.
The disclosure provides a method of treating or preventing a bacterial infection in a subject comprising administering a therapeutically effective amount of a combination of a bacterial type IIA topoisomerase inhibitor, or a pharmaceutically acceptable salt thereof and a compound Formula I, or a pharmaceutically acceptable salt thereof, to the subject, where the compound of Formula I is (Formula (I)) where the variables, e.g. Y1, Y2, and R1-R4, are described herein. The bacterial type IIA topoisomerase inhibitor can be a quinolone antibiotic such as ciprofloxacin.
UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Gharia, Asmaysinh
Malliaras, George
Abrégé
The present invention provides devices and methods for electroporation. Embodiments of the invention provide an electroporation device, the device having: a microfluidic channel with a fluid inlet and a fluid outlet; and a pair of interdigitated electrodes formed within said channel, wherein said electrodes are coated with PEDOT:PSS on a contact surface which is in contact with fluid in the channel. Other embodiments of the invention provide a method of performing electroporation on cells in a sample, the method including the steps of: introducing the sample into a chamber having a pair of electrodes each having a coating of PEDOT:PSS on a contact surface which is in contact with the sample; and applying oscillating stimulation voltage signals to the sample using the electrodes, wherein the stimulation voltage signals are applied so as to stimulate electroporation in the cells.
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p. ex. par magnétisme, par des ondes sonores
47.
DETECTION OF HEPATITIS C VIRUS RIBONUCLEIC ACID FROM WHOLE BLOOD USING REVERSE TRANSCRIPTION LOOP-MEDIATED ISOTHERMAL AMPLIFICATION
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Pauly, Matthew David
Weis Torres, Sabrina
Ganova-Raeva, Lilia Milkova
Kamili, Saleem
Hayden, Tonya
Abrégé
Rapid, sensitive, and low-cost methods for the detection of hepatitis C virus (HCV) RNA in biological samples using reverse transcription loop-mediated isothermal amplification (RT-LAMP) reactions and rationally designed primers are described. The RT-LAMP primers can amplify nucleic acid from all HCV genotypes. The methods, primers and kits of the disclosure are suitable for point-of-care diagnostics. Efficient methods for isolation of HCV RNA from whole blood are also described.
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
48.
METHODS FOR PRODUCING STABLE HUMAN CHONDROCTYES AND THEIR USE FOR PROMOTING CARTILLAGE GROWTH AND REPAIR
THE UNITED STATES OF AMERICA, as represented by the secretary, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
CAMBRIDGE ENTERPRISE LIMITED (Royaume‑Uni)
Inventeur(s)
Robey, Pamela Gehron
Gadomski, Stephen Joseph
Mccaskie, Andrew
Abrégé
in vitroin vivoin vivo. In some aspects, disclosed are methods of producing these non-natural human chondrocytes. In further aspects, disclosed are methods of using these non-natural human chondrocytes, such as for promoting cartilage growth and/or repair.
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
49.
ANTIBODY-GUIDED PCSK9-MIMICKING IMMUNOGENS LACKING 9-RESIDUE SEQUENCE OVERLAP WITH HUMAN PROTEINS
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Kwong, Peter D.
Chuang, Gwo-Yu
Zhang, Baoshan
Kong, Wing-Pui
Wang, Yiran
Chao, Cara
Mascola, John R.
Ou, Li
Zhou, Tongqing
Yang, Yongping
Liu, Bohan
Cheng, Cheng
Biner, Daniel W.
Rawi, Reda
Abrégé
The present disclosure describes the grafting of epitope residues from human PCSK9 to non-human PCSK9 or PCSK9 structural homologs and elimination of 9-mers oligopeptides that are found in human protein to reduce self-targeting response. Anti-genicity of the epitope-scaffold constructs was demonstrated toward anti-human PCSK9 antibodies. similar to wild type human PCSK9. It was shown that disclosed PCSK9 immunogens could significantly reduce LDL and cholesterol levels in immunized mice.
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance
C07D 311/96 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle, condensés avec d'autres cycles condensés en spiro avec des carbocycles ou avec des systèmes carbocycliques
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
51.
SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
AMPX TECHNOLOGIES, INC. (USA)
Inventeur(s)
Gandjbakhche, Amir Hossein
Nguyen, Thien T.
Zhang, Zeyu
Park, Soongho
Downey, George H.
Khaligh, Alireza
Khaksari, Kosar
Abrégé
The disclosure provides systems and a protocol for monitoring the health of a fetus and a mother during pregnancy. A wearable device utilizing near-infrared spectroscopy (NIRS) is disclosed for monitoring a number of parameters associated with placental tissue, the fetus, and/or the mother. The device includes one or more light sources and one or more photodetectors, each photodetector separated from a particular light source by a corresponding separation distance. The device further includes a processor configured to collect data based on intensity information collected by the plurality of photodetectors responsive to activation of one or more of the plurality of light sources. The data is used to estimate an oxygen saturation level for a layer of placental tissue in a uterus of a mother, or maternal physiological signals including respiratory functions, cardiac functions, oxygenation levels, or fetal cardiac functions.
A61B 5/024 - Mesure du pouls ou des pulsations cardiaques
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A61B 5/1464 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale spécialement adaptés pour des tissus fœtaux
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/01 - Mesure de la température de parties du corps
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
52.
COMPOSITION FOR PREVENTING OR TREATING SYSTEMIC CAPILLARY LEAK SYNDROME
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Yoo, Jin-San
Lee, Weon Sup
Shim, Sang Ryeol
Jeong, Boyoung
Park, Cheon Ho
Lee, Eun Ah
Park, Beomyong
Kang, Nu Ri
Kim, Bu Yeon
Druey, Krik Matthew
Ablooglu, Ararat Jan
Desai, Abhishek Ajikumar
Abrégé
The present invention pertains to a composition for preventing or treating systemic capillary leak syndrome (SCLTimeS), the composition containing a Tie2 receptor activating agent as an active ingredient.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61P 9/14 - VasoprotecteursAntihémorroïdauxMédicaments pour le traitement des varicesStabilisateurs capillaires
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
53.
RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS LACKING AN IMMUNODOMINANT T CELL EPITOPE AND USE THEREOF
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Jolles-Mazor, Ronit
Bing, Sojin
Abrégé
Recombinant adeno-associated virus (AAV) vectors encoding a modified VP1 protein lacking an immunodominant T cell epitope, as well as AAV vector particles containing the modified VP1 protein, are described. Use of the recombinant AAV vectors and vector particles as improved gene therapy vectors with reduced immunogenicity is also described. Isolated VP1 peptides containing an immunodominant T cell epitope, and use thereof, is further described.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE GENERAL HOSPITAL CORPORATION, D/B/A MASSACHUSETTS GENERAL HOSPITAL (USA)
Inventeur(s)
Mueller, Geoffrey A.
Pedersen, Lars C.
Min, Jungki
Patil, Sarita
Abrégé
Provided herein are hypoallergenic mutant Ara h proteins, including Ara h 2 and Ara h 6, and uses thereof in treating allergic or anaphylactic responses to peanut allergens, immunotherapy and diagnostics.
United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventeur(s)
Verma, Meghav
Michael, Samuel
Janiszewski, John
Liu, Chang
Covey, Thomas R.
Abrégé
A method of processing a sample plate containing a plurality of samples includes aspirating simultaneously, from the sample plate, a first sample droplet from a first sample of the plurality of samples with a first pipette and a second sample droplet from a second sample of the plurality of samples with a second pipette. The sample plate also includes dispensing sequentially, from the first pipette and the second pipette, the first sample drop and the second sample drop into an open port interface (OPI).
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
56.
METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Cafri, Gal
Robbins, Paul F.
Gartner, Jared J.
Rosenberg, Steven A.
Abrégé
Disclosed are methods of preparing an isolated population of dendritic cells, isolated populations of dendritic cells prepared by the methods, and pharmaceutical compositions comprising the isolated population of dendritic cells. Also disclosed are methods of treating or preventing cancer using the isolated population of dendritic cells or pharmaceutical compositions.
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
57.
EPSTEIN-BARR VIRUS GLYCOPROTEIN 42 IMMUNOGENS FOR VACCINATION AND ANTIBODY DISCOVERY
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Cohen, Jeffrey I.
Bu, Wei
Dowdell, Kennichi C.
Marcotrigiano, Joseph
Abrégé
Modified Epstein-Barr virus (EBV) glycoprotein 42 (gp42) polypeptides that retain immunogenicity, but are impaired for binding HLA class II molecules are described. Use of the modified gp42 polypeptides in immunogenic compositions, such as in self-assembling protein nanoparticle compositions, is also described. Methods for screening B cells that express gp42-specific monoclonal antibodies using the modified gp42 polypeptides as a probe, are also described.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Nguyen, Nam V.
Kim, Jongwoo
Kodati, Shilpa
Abrégé
Systems and methods for a convolutional neural network classifier to detect retinal vasculitis in color fundus photographs of patients with uveitis using a feature extraction and classification operations are disclosed herein.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
KUROME THERAPEUTICS, INC. (USA)
Inventeur(s)
Hoyt, Scott Bryan
Starczynowski, Daniel T.
Thomas, Craig Joseph
Rosenbaum, Jan Susan
Abrégé
Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
60.
METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS BY DETECTING A BIOMARKER IN THE CEREBROSPINAL FLUID
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Blazier, Anna
Ofengeim, Dimitry
Turner, Timothy J.
Wirak, Gregory
Jacobsen, Steven
Reich, Daniel S.
Gaitan, Maria Inès
Raza, Syed Ali
Abrégé
Provided herein are methods and immune biomarkers that identify progression and treatment options for multiple sclerosis (MS). Also provided are materials and methods for the prognosis, staging, and monitoring of MS in a sample and include methods of determining a subject as being at risk of developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and/or CCL3 in cerebrospinal fluid (CSF) in the subject; and administering a pharmaceutically effective amount of a treatment (e.g., tolebrutinib and potentially one or more additional therapies, such as an anti-CD20 therapy) to the subject.
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
61.
HUMAN PAPILLOMAVIRUS, VARICELLA-ZOSTER VIRUS, AND RABIES VIRUS ANTIGENS AND USES THEREOF IN CANCER IMMUNOTHERAPY
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Cuburu, Nicolas
Bialkowski, Lukasz
Schiller, John
Sethi, Shiv K.
Abrégé
Provided herein are varicella-zoster virus vaccine, human papillomavirus vaccine, and Rabies vaccine antigens, compositions thereof, and uses thereof in cancer immunotherapy and cancer treatment.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Ishii, Kazusa
Hinrichs, Christian
Abrégé
Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a CD22 amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Appella, Daniel H.
Robello, Marco
Abrégé
Disclosed is a compound of formula (I) or salt thereof: Formula (I) for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.
A61K 31/4355 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'oxygène comme hétéro-atome du cycle
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Inglese, James
Dranchak, Patricia Karen
Abrégé
Disclosed herein are assays for detecting interaction of a target of interest (TOI) with a compound. Specifically, the disclosed assays are based on the idea that compound-induced change in the structural conformation ensemble distribution environment of a label attached to the TOI may be used to detect interaction of the compound with a TOI. The label may be part of a complementary reporter system that uses a substrate to produce a fluorescent or chemiluminescent signal. Alternatively, the label may be detected directly by fluorescence.
C12Q 1/66 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une luciférase
G01N 33/542 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec inhibition stérique ou modification du signal, p. ex. extinction de fluorescence
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Krynitsky, Jonathan
Jones, Thomas T.
Gordon, Patricia B.
Tanner, Kandice
Abrégé
An intubation system for directing water to and from an aquatic specimen during the visual observation thereof can include an intubation chamber that facilitates the guided direction of an inflow tube and a plurality of outflow tubes to the specimen. The intubation chamber can be manufactured by an additive manufacturing process to include various inflow and outflow tube channels in a relative complex geometry. An inflow channel guide may be included and can be fitted to the intubation chamber to guide the inflow tube to the intended location of the head of the specimen. The intubation system may also include a brace plate having a chamber opening for the correct positioning of the intubation chamber with respect to the system. A drug delivery system can include a syringe pump and a multiport junction to fluidly introduce a liquid drug to the inflow tube upstream of the intubation chamber.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Mahajan, Pankaj S.
Smith, Steven J.
Hughes, Stephen H.
Zhao, Zuezhi
Burke, Jr., Terrence R.
Abrégé
A compound, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, having a structure of Formula (I) wherein R1, R2, X and a are defined in the claims.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventeur(s)
Pastan, Ira H.
Wei, Junxia
Onda, Masanori
Bera, Tapan
Ho, Mitchell
Abrégé
Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 14/21 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Pseudomonadaceae (F)
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
69.
SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Swenson, Rolf E.
Ettedgui-Benjamini, Jessica H.
Woodroofe Hitko, Carolyn
Cherukuri, Murali K.
Raju, Natarajan
Abrégé
Disclosed are perfluorinated SABRE catalysts comprising a d-block element and a perfluorinated ligand, wherein the perfluorinated ligand is of Formula (I): [Lm-(NHC)—(Y—Z)q] or a salt thereof. Also disclosed is a method of preparing a hyperpolarized substrate comprising a ½ spin nucleus or nuclei using the perfluorinated SABRE catalysts, and isolating the resulting hyperpolarized substrate for administration to an animal. Further disclosed is a method of imaging a tissue of an animal suspected of having a disease or condition.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Sullivan, Nancy J.
Misasi, John
Niezold, Thomas
Zhao, Bingchun
Leigh, Kendra
Hunegnaw, Ruth
Abrégé
Monoclonal antibodies that bind Sudan virus (SUDV) and/or Ebola virus (EBOV) glycoprotein (GP) with nanomolar affinity are described. The monoclonal antibodies were developed by single-cell sorting of B cells obtained from non-human primate and human subjects previously immunized with Ebola (Zaire) virus (EBOV) and Sudan virus (SUDV) glycoprotein. Use of the monoclonal antibodies for treating, inhibiting, and detecting infection by SUDV and EBOV is also described.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Sullivan, Nancy J.
Misasi, John
Niezold, Thomas
Zhao, Bingchun
Leigh, Kendra
Hunegnaw, Ruth
Pegu, Amarendra
Koup, Richard
Mulangu, Jean Christophe Sabue
Abrégé
Monoclonal antibodies and bispecific monoclonal antibodies that bind Sudan virus (SUDV) and/or Ebola virus (EBOV) glycoprotein (GP) with nanomolar affinity are described. The monoclonal antibodies were developed by single-cell sorting of B cells obtained from non-human primate and human subjects previously immunized with Ebola (Zaire) virus (EBOV) and Sudan virus (SUDV) glycoprotein. Use of the monoclonal antibodies and bispecific antibodies for treating, inhibiting, and detecting infection by SUDV and EBOV is also described.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Hernandez, Jonathan Matthew
Pohida, Thomas J.
Garmendia, Marcial Antonio
Ruff, Samantha Marilyn
Wach, Michael Martin
Gupta, Shreya
Mcdonald, James
Remmert, Kirsten
Rossi, Alexander Joseph
Abrégé
Ex vivo analysis can be performed by mounting a portion of live tissue resected from a patient on a sample platform. Using the sample platform, the resected tissue portion can be positioned within a perfusion chamber. Perfusate is flowed through the perfusion chamber and into contact with the resected tissue portion such that diffusion of oxygen occurs between the perfusate and the resected tissue portion. During the flowing, the resected tissue portion maintains a competent immune system. Drugs can be added to the perfusate flow to ascertain the effect on the tissue. The sample platform is designed to be removable from the perfusion chamber for analysis of the tissue by imaging or other investigation techniques, for experimental treatment, or for any other purpose. After removal, the sample platform can be returned to the perfusion chamber for continued viability of the tissue.
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
73.
MONOCLONAL ANTIBODIES FOR TREATING SARS-COV-2 INFECTION
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Zhou, Tongqing
Misasi, John, Nicholas
Wang, Lingshu
Koup, Richard, Alan
Sullivan, Nancy, J.
Mascola, John, R.
Doria-Rose, Nicole, Amy
Douek, Daniel, Cesar
Schramm, Chaim, Aryeh
Yang, Eun Sung
Chen, Man
Shi, Wei
Zhang, Yi
Birungi-Huff, Kevina, Maria, Nabireka
Bush, Sabrina, Marie
Musayev, Maryam
Abrégé
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies. In some aspects, the antibodies bind a BA.4 or BA.5 variant. In other aspects, the antibodies bind BQ1.1 and/or XBV.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Nguyen, Thien
Gandjbakhche, Amir Hossein
Park, Soongho
Hill, Brian Y.
Abrégé
StO2StO22 StO2 2 2 parameter can be calculated for each distinct source-detector pair of an optical device, reducing the cost and complexity of the device and enabling further miniaturization.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/0205 - Évaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p. ex. de l'état cardiaque et respiratoire
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Tolia, Niraj, Harish
Dickey, Thayne, Henderson
Gupta, Richi
Shi, Dashuang
Abrégé
Plasmodium Plasmodium spp P48/45 protein. Such modified proteins retain an epitope that elicits neutralizing antibodies against the P48/45 protein. Also disclosed are nucleic acid molecules encoding the modified proteins, nanoparticles displaying the modified protein, as well as methods of using the modified proteins and nanoparticles.
A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
C07K 16/20 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains provenant de protozoaires
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Appella, Daniel H.
Zheng, Hongchao
Clausse, Victor
Amarasekara, Harsha C.
Abrégé
nn-L-P (I), wherein T is a thyclotide unit of the formula:, wherein the thyclotide units are optionally intercepted by segments of polypeptide which can be the same as or different from P, n is about 5 to about 25, L is a linker, P is a polypeptide, and B is a nucleobase or a heterocyclyl moiety. Also disclosed are pharmaceutical compositions and methods of treating diseases such as cancers by administering an effective amount of a thyclotide-peptide conjugate.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE DE MONTPELLIER (France)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Mekary, Jacinthe
Touhami, Jawida
Youkharibache, Philippe
Giovannini, Donatella
Sitbon, Marc
Abrégé
in vitroin vivoin vivo methods of specifically detecting or/and measuring the level of ASCT1, and to the use of said polypeptides in diagnosis and therapy.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Clark, Iain
Boritz, Eli, A.
Abate, Adam
Abrégé
The present disclosure provides materials and methods for detecting the presence of nucleic acids, including RNA and/or DNA, from single cells. The present disclosure describes methods and workflows to detect, sort, sequence nucleic acids from rare cell types using various encapsulation, reverse transcription, amplification and detection techniques that allows linking of a single cell's genotype and phenotype.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
UNIVERSITY OF MODENA AND REGGIO EMILIA (Italie)
Inventeur(s)
Becerra, Sofia Patricia
Bernardo-Colon, Alexandra
Marigo, Valeria
Bighinati, Andrea
Abrégé
Provided herein are compositions and methods for treating retinal degeneration, such as an inherited retinal degeneration. In some examples, the compositions include a pigment epithelium-derived factor (PEDF) protein or a peptide thereof. Compositions including a PEDF 17mer[H105A] peptide in an eye drop formulation or an adeno-associated virus vector including a nucleic acid encoding a PEDF protein or PEDF 17mer[H105A] peptide are provided. Methods for treating retinal degeneration include administering a provided eyedrop formulation or adeno-associated virus vector to an eye of a subject with retinal degeneration.
A61K 38/03 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
80.
NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST WESTERN, EASTERN, AND VENEZUELAN EQUINE ENCEPHALITIS VIRUS (EEV)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventeur(s)
Roederer, Mario
Ko, Sungyoul
Sutton, Matthew Scott
Kwong, Peter D.
Verardi, Raffaello
Rawi, Reda
Shen, Chen-Hsiang
Fox, Julie
Callahan, Victoria
Cerutti, Gabriele
Casner, Ryan Gavin
Shapiro, Lawrence
Abrégé
Disclosed herein are isolated antibodies that bind one or more species of alphaviruses. In certain aspects, the disclosed antibodies bind and neutralize three or more species of alphaviruses. Also disclosed are methods of using the disclosed antibodies to prevent infection of a cell with an alpha virus, to protect an individual from alphavirus infection, and to treat an individual for an alphavirus infection.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Mishra, Nischay
Lipkin, Walter, Ian
Dubey, Sunil, Kumar
Hensley, Lisa
Abrégé
Peptides, platforms and methods for detecting antibody responses to filovirus infections, detecting antibody responses to EBOV infection, and detecting antibody responses to vaccination by EBOV vesicular stomatitis virus-based vaccine.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
82.
TOPOISOMERASE III (TOP3) INHIBITORS AND ANTIVIRAL COMPOUNDS BASED ON BISACRIDINES
UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Vassilev, Ventzislav Bojidarov
Mallett, Corey
Rouxel, Ronan
Blais, Normand
Kanekiyo, Masaru
Graham, Barney S.
Abrégé
The present invention relates to a carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (USA)
Inventeur(s)
Huang, Shar-Yin, Naomi
Pommier, Yves, Georges
Wang, Wenjie
Saha, Sourav
Wang, Weidong
Zhang, Tianyi
Brosh, Robert
Sommers, Joshua
Kennedy, Debbie
Shi, Pei-Yong
Garcia-Blanco, Mariano
Tse-Dinh, Yuk-Ching
Abrégé
Methods and polymethine bridge-containing cyanine compositions for inhibiting topoisomerase III beta (TOP3B), RNA-dependent RNA polymerases, and RNA-dependent DNA polymerases and conferring antiviral and/or anti-cancer activity are disclosed.
UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Vassilev, Ventzislav Bojidarov
Mallett, Corey
Rouxel, Ronan
Blais, Normand
Kanekiyo, Masaru
Graham, Barney S.
Abrégé
The present invention relates to influenza virus immunisation using at least one influenza HA stem polypeptide in conjunction with squalene emulsion adjuvants, and to related aspects.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Kochenderfer, James N.
Lam, Norris
Abrégé
An aspect of the invention provides nucleic acids comprising a nucleotide sequence encoding chimeric antigen receptor (CAR) amino acid constructs. Polypeptides, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Lederman, Robert J.
Yildirim, Dursun Korel
Abrégé
A myotomy catheter for performing longitudinal myocardial incisions is provided. In one example, a catheter-based heart incision apparatus comprises an anchor stabilization and orientation catheter system with at least one anchor element and an incision catheter including a lacerator configured to move along an incision trajectory oriented by the at least one anchor element.
A61M 25/01 - Introduction, guidage, avance, mise en place ou maintien en position des cathéters
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
88.
DIRECTED ACETYLATION OF MRNA THROUGH ENGINEERED SNORNA ADAPTERS
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Oberdoerffer, Shalini
Schiffers, Sarah
Abrégé
The disclosure provides engineered nucleotide sequences, vectors, and pharmaceutical compositions that can be used in methods for treating a disease or disorder with an associated haploinsufficiency and/or cancer.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c.-à-d. autres que des liaisons 3'-5' phosphodiester
89.
REBALANCING THE IMMUNE SYSTEM THROUGH DEPLETION OF MYELOID-BIASED HEMATOPOIETIC STEM CELLS
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Ross, Jason B.
Myers, Lara
Noh, Joseph
Hasenkrug, Kim J.
Weissman, Irving L.
Abrégé
The present disclosure provides a clinically applicable method to re-balance production of hematopoietic cells in a mammal, including without limitation an aged mammal, by selective depletion of myeloid-biased hematopoietic stem cells (my-HSC). This selective depletion provides for increased production of lymphoid cells relative to myeloid cells.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
90.
HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST BRAF WITH V600E MUTATION
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Yu, Zhiya
Ade, Catherine M.
Sporn, Matthew J.
Yang, James C.
Hanada, Ken-Ichi
Abrégé
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a human BRAFV600E amino acid sequence. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Krishna, Sri
Levi, Shoshana T.
Yoseph, Rami
Lowery, Iii, Frank J.
Nah, Shirley K.
Robbins, Paul F.
Rosenberg, Steven A.
Abrégé
CDKN2ACDKN2A. The TCRs may recognize mutated CDKN2A peptide presented by an HLA-A molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Kratzmeier, Sabina, A.
Kaplan, Rosandra, N.
Contreras Burrola, Cristina
Hedrick, Catherine
Alimadadi, Ahmad
Abrégé
The invention provides a method for predicting the susceptibility of a patient suffering from a cancer or a myeloid-mediated disease to immunotherapy. Furthermore, the invention provides a method for treating a patient suffering from a cancer or a myeloid-mediated disease with immunotherapy. In accordance with these embodiments, the inventive method includes assaying myeloid cells obtained from the patient prior to treatment for the expression of CXCR3. The invention also provides a genetically engineered myeloid cell (GEMy) in which the expression of CXCR3 is modulated (up- or down-regulated). The invention further provides a composition comprising the inventive GEMy and a pharmaceutically acceptable carrier. The invention also provides a method for treating a patient in need of immunotherapy comprising administering the inventive composition to a patient.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Jacobson, Kenneth A.
Jung, Young-Hwan
Wen, Zhiwei
Abrégé
Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R1-R8, X, Y, Z, X′, Y′, Z′, and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.
Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R1-R8, X, Y, Z, X′, Y′, Z′, and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.
C07D 211/34 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
C07D 205/04 - Composés hétérocycliques comportant des cycles à quatre chaînons ne contenant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07D 205/12 - Composés hétérocycliques comportant des cycles à quatre chaînons ne contenant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 207/08 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés, substitués par des hétéro-atomes, liés aux atomes de carbone du cycle
C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons
C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile liés en position 4
C07D 221/04 - Systèmes cycliques condensés en ortho ou en péri
C07D 223/04 - Composés hétérocycliques contenant des cycles à sept chaînons ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène, des atomes d'halogènes, des radicaux hydrocarbonés ou hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 225/02 - Composés hétérocycliques contenant des cycles de plus de sept chaînons ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles
C07D 249/06 - Triazoles-1, 2, 3Triazoles-1, 2, 3 hydrogénés avec des radicaux aryle liés directement aux atomes du cycle
C07D 261/08 - Composés hétérocycliques contenant des cycles oxazole-1, 2 ou oxazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant plusieurs liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/10 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 413/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (USA)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (Royaume‑Uni)
Inventeur(s)
Lynn, Geoffrey Martin
Garliss, Christopher Martin O'Brien
Ishizuka, Andrew Scott
Baharom, Faezzah
Seder, Robert Alan
Ramirez-Valdez, Ramiro Andrei
Abrégé
The present disclosure relates to methods of treating cancer in subjects by a two-part treatment regime comprising a first treatment that provides antigen-specific CD4+ and/or CD8+ T cells in the subject and a second treatment, administered after a time interval, that induces systemic and/or tumor-specific inflammation in the subject.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Lynn, Geoffrey Martin
Garliss, Christopher Martin O'Brien
Ishizuka, Andrew Scott
Wells, Hugh Clarke
Abrégé
The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker,[ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
96.
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Egwuagu, Charles E.
Kang, Minkyung
Abrégé
In an embodiment, the invention provides an isolated population of exosomes comprising interleukin-27 (IL-27) or interleukin-35 (IL-35). In an embodiment, the invention also provides a method of preparing a population of exosomes comprising interleukin-27 (IL-27), the method comprising: (a) isolating CD19+B2 cells or B1a cells; (b) activating the isolated cells with a LPS or a BCR agonist to provide activated cells; and (c) isolating exosomes secreted from the activated cells. In an embodiment, the invention also provides a method of preparing a population of exosomes comprising interleukin-35 (IL-35), the method comprising: (a) isolating CD138+plasma cells; (b) activating the isolated cells with a LPS or a BCR agonist to provide activated cells; and (c) isolating exosomes secreted from the activated cells. Additional embodiments of the invention are as described.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Marzi, Andrea M.
Feldmann, Heinrich U.
Abrégé
A recombinant vesicular stomatitis virus (VSV) in which the VSV G gene is replaced with the glycoprotein (GP) gene of Sudan virus (SUDV) is described. The recombinant VSV, referred to as VSV-SUDV, can be used as a live attenuated vaccine for the treatment or prophylaxis of Sudan virus disease (SVD). VSV-SUDV replicates in inoculated subjects, which induces strong innate and adaptive immune responses. Efficacy studies in non-human primates demonstrated that a single intramuscular vaccination protected animals from a lethal challenge dose of SUDV even when vaccination occurred only seven days prior to challenge. In addition, pre-exposure to the VSV vector did not inhibit a robust response to the SUDV GP component of the vaccine.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Liu, Qing-Rong
Zhu, Min
Egan, Josephine M.
Abrégé
Methods of treating a subject with diabetes or Alzheimer's disease with a disclosed islet amyloid polypeptide (IAPP) isoform or peptide are provided. Methods of detecting IAPP isoforms or peptides are also provided.
A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
99.
METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventeur(s)
Lu, Yong-Chen
Fitzgerald, Peter
Zheng, Zhili
Rosenberg, Steven A.
Abrégé
Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine